Defining the Proximal Border of the Huntington Disease Candidate Region by Multipoint Recombination Analyses

Genomics ◽

10.1006/geno.1993.1236 ◽

1993 ◽

Vol 16 (3) ◽

pp. 599-604 ◽

Author(s):

Mette I. Skraastad ◽

Karien E. de Rooij ◽

Pia A.M. de Koning Gans ◽

Aart Verwest ◽

Maria Vegter-van der Vlis ◽

...

Keyword(s):

Huntington Disease ◽

Candidate Region ◽

Proximal Border

Download Full-text

Identification of multiple CpG islands and associated conserved sequences in a candidate region for the Huntington disease gene

Genomics ◽

10.1016/0888-7543(91)90039-h ◽

1991 ◽

Vol 11 (4) ◽

pp. 1113-1124 ◽

Author(s):

Bernhard Weber ◽

Colin Collins ◽

David Kowbel ◽

Olaf Riess ◽

Michael R. Hayden

Keyword(s):

Huntington Disease ◽

Disease Gene ◽

Cpg Islands ◽

Candidate Region ◽

Conserved Sequences ◽

Huntington Disease Gene

Download Full-text

Sequence-tagged sites (STSs) spanning 4p16.3 and the Huntington disease candidate region

Genomics ◽

10.1016/0888-7543(92)90204-6 ◽

1992 ◽

Vol 13 (1) ◽

pp. 75-80 ◽

Author(s):

James F. Gusella ◽

Michael R. Altherr ◽

Andrea I. McClatchey ◽

Lynn A. Doucette-Stamm ◽

Dan Tagle ◽

...

Keyword(s):

Huntington Disease ◽

Candidate Region ◽

Sequence Tagged Sites

Download Full-text

Narrowing down the candidate region for childhod absence epilepsy in 8q24 and characterization of a candidate gene, T-STAR

Neuroscience Research ◽

10.1016/s0168-0102(00)81566-7 ◽

2000 ◽

Vol 38 ◽

pp. S120

Author(s):

Y Sugimoto

Keyword(s):

Candidate Gene ◽

Absence Epilepsy ◽

Candidate Region

Download Full-text

Progressive myoclonus epilepsy: a differential diagnosis from juvenile chorea Huntington disease

Neuropediatrics ◽

10.1055/s-0033-1337705 ◽

2013 ◽

Vol 44 (02) ◽

Author(s):

M Gosk ◽

F Laccone ◽

P Burfeind ◽

G Bernert

Keyword(s):

Differential Diagnosis ◽

Huntington Disease ◽

Chorea Huntington ◽

Progressive Myoclonus Epilepsy ◽

Myoclonus Epilepsy

Download Full-text

Faculty Opinions recommendation of Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1019373.218521 ◽

2004 ◽

Author(s):

Thomas Neufeld

Keyword(s):

Mouse Models ◽

Huntington Disease ◽

Polyglutamine Expansions

Download Full-text

Faculty Opinions recommendation of Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1017842.207466 ◽

2004 ◽

Author(s):

M Flint Beal

Keyword(s):

Mouse Model ◽

Huntington Disease

Download Full-text

Faculty Opinions recommendation of The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.4003957.3763055 ◽

2010 ◽

Author(s):

Giovanni Neri

Keyword(s):

Huntington Disease ◽

Genetic Disease ◽

Prenatal Testing ◽

Genetic Status ◽

Download Full-text

Faculty Opinions recommendation of Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718086977.793485064 ◽

2013 ◽

Author(s):

George Perry

Keyword(s):

Huntington Disease ◽

Download Full-text

Faculty Opinions recommendation of Substance abuse may hasten motor onset of Huntington disease: Evaluating the Enroll-HD database.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727261803.793537341 ◽

2017 ◽

Author(s):

Victor Fung ◽

Florence Chang

Keyword(s):

Substance Abuse ◽

Huntington Disease ◽

Download Full-text

Nanotechnology: its application in treating Neurodegenerative diseases

CNS & Neurological Disorders - Drug Targets ◽

10.2174/1871527319666200916121515 ◽

2020 ◽

Vol 19 ◽

Author(s):

Falaq Naz ◽

Yasir Hasan Siddique

Keyword(s):

Quality Of Life ◽

Neurodegenerative Diseases ◽

Blood Brain Barrier ◽

Huntington Disease ◽

Treatment Strategies ◽

Present Review ◽

Brain Barrier ◽

Treatment Level ◽

: Neurodegenerative diseases including Alzheimer’s, Parkinson’s and Huntington disease are have serious concern due to its effect on the quality of life of affected persons. Neurodegenerative diseases have some limitations for both diagnostic as well as at treatment level. Introducing nanotechnology, for the treatment of these diseases may contribute significantly in solving the problem. There are several treatment strategies for the neurodegenerative diseases, but their limitations are the entry into the due to the presence of the blood-brain barrier (BBB). The present review highlights the application of nanotechnology during last 20 years for the treatment of neurodegenerative diseases.

Download Full-text